Therefore, the main objective of this study was to evaluate progression free and overall survival (PFS and OS) after surgery and adjuvant treatment of tumors formerly classified as diffuse IDH wt astrocytomas WHO grade II or III in the largest cohort so far. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).